In breast cancer, differential methylation patterns in multiple immune checkpoint ligand promoters, including PD-L1, CTLA-4, LAG-3, and TIM-3 upregulate their expression compared to normal tissue and correlate with poor patient prognosis [55]. Here, CD274 is linked to breast carcinoma.